These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22815703)

  • 1. Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.
    Holtan SG; Steen PD; Foster NR; Erlichman C; Medeiros F; Ames MM; Safgren SL; Graham DL; Behrens RJ; Goetz MP
    PLoS One; 2012; 7(7):e39285. PubMed ID: 22815703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
    Greco FA; Rodriguez GI; Shaffer DW; Hermann R; Litchy S; Yardley DA; Burris HA; Morrissey LH; Erland JB; Hainsworth JD
    Oncologist; 2004; 9(6):644-52. PubMed ID: 15561808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial.
    Hainsworth JD; Spigel DR; Raefsky EL; Kuzur ME; Yost K; Kommor M; Litchy S; Greco FA
    Cancer; 2005 Nov; 104(9):1992-7. PubMed ID: 16130138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.
    Hainsworth JD; Spigel DR; Clark BL; Shipley D; Thompson DS; Farley C; West-Osterfield K; Lane CM; Cescon T; Bury MJ; Greco FA
    Cancer J; 2010; 16(1):70-5. PubMed ID: 20164695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Satoh Y; Takai D; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Mohri D; Kawakubo K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tada M; Yatomi Y; Koike K
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):85-92. PubMed ID: 23053265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
    Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
    Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
    Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
    Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
    Culine S; Lortholary A; Voigt JJ; Bugat R; Théodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Allouache J; Goupil A; Négrier S; Viala J; Petrow P; Bouzy J; Laplanche A; Fizazi K;
    J Clin Oncol; 2003 Sep; 21(18):3479-82. PubMed ID: 12972523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
    Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
    Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
    Bajetta E; Di Bartolomeo M; Mariani L; Cassata A; Artale S; Frustaci S; Pinotti G; Bonetti A; Carreca I; Biasco G; Bonaglia L; Marini G; Iannelli A; Cortinovis D; Ferrario E; Beretta E; Lambiase A; Buzzoni R;
    Cancer; 2004 Jan; 100(2):279-87. PubMed ID: 14716761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
    Lipton A; Campbell-Baird C; Witters L; Harvey H; Ali S
    J Clin Gastroenterol; 2010 Apr; 44(4):286-8. PubMed ID: 20216081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
    Schuette W; Nagel S; Juergens S; Bork I; Wollschlaeger B; Schaedlich S; Blankenburg T
    Clin Lung Cancer; 2005 Sep; 7(2):133-7. PubMed ID: 16179101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
    Chaudhary UB; Verma N; Keane T; Gudena V
    Am J Clin Oncol; 2014 Apr; 37(2):188-93. PubMed ID: 23241501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
    Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.